Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Aug 23;120(8):1581-8.
doi: 10.1182/blood-2012-02-408336. Epub 2012 May 30.

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

Michael R Loken  1 , Todd A Alonzo, Laura Pardo, Robert B Gerbing, Susana C Raimondi, Betsy A Hirsch, Phoenix A Ho, Janet Franklin, Todd M Cooper, Alan S Gamis, Soheil Meshinchi
Affiliations
Clinical Trial

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

Michael R Loken et al. Blood. .

Abstract

Early response to induction chemotherapy is a predictor of outcome in acute myeloid leukemia (AML). We determined the prevalence and significance of postinduction residual disease (RD) by multidimensional flow cytometry (MDF) in children treated on Children's Oncology Group AML protocol AAML03P1. Postinduction marrow specimens at the end of induction (EOI) 1 or 2 or at the end of therapy from 249 patients were prospectively evaluated by MDF for RD, and presence of RD was correlated with disease characteristics and clinical outcome. Of the 188 patients in morphologic complete remission at EOI1, 46 (24%) had MDF-detectable disease. Those with and without RD at the EOI1 had a 3-year relapse risk of 60% and 29%, respectively (P < .001); the corresponding relapse-free survival was 30% and 65% (P < .001). Presence of RD at the EOI2 and end of therapy was similarly predictive of poor outcome. RD was detected in 28% of standard-risk patients in complete remission and was highly associated with poor relapse-free survival (P = .008). In a multivariate analysis, including cytogenetic and molecular risk factors, RD was an independent predictor of relapse (P < .001). MDF identifies patients at risk of relapse and poor outcome and can be incorporated into clinical trials for risk-based therapy allocation. This study was registered at www.clinicaltrials.gov as NCT00070174.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of residual disease in specific cytogenetic, risk, molecular, and response groups in patients in morphologic complete remission (CR) after one course of chemotherapy. EOI indicates end of induction; ITD, internal tandem duplication; and RD, residual disease.
Figure 2
Figure 2
Relapse risk and relapse-free survival from end of induction 1. Relapse risk (A) and relapse-free survival (B) from end of induction 1 in patients with morphologic response to induction chemotherapy. RD indicates residual disease.
Figure 3
Figure 3
Overall survival of patients with morphologic induction failure diagnosed on the basis of disease detection by multidimensional flow cytometry. EOI indicates end of induction; and RD, residual disease.
Figure 4
Figure 4
Relapse risk and relapse-free survival by residual disease (RD) status at the end of induction 2. Relapse risk and relapse-free survival by residual disease status at the end of induction 2 (A-B) and at the end of therapy (C-D).
Figure 5
Figure 5
Relapse risk and relapse-free survival from end of therapy. Relapse risk (A) and relapse-free survival (B) from end of therapy for patients with no documented residual disease (RD) during therapy (no RD), with RD at the end of therapy (RD positive), and without RD at the end of therapy with previously documented RD.
Figure 6
Figure 6
Relapse risk on the basis of residual disease (RD) threshold of 1%.
Figure 7
Figure 7
Relapse-free survival on the basis of the presence or absence of residual disease (RD). Relapse-free survival on the basis of the presence or absence of RD in patients with standard-risk (A), favorable-risk (B) or high-risk (C) acute myeloid leukemia.
See this image and copyright information in PMC

Comment in

References

    1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–565. - PMC - PubMed
    1. Terstappen LW, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol. 1990;2(4):229–240. - PubMed
    1. Terstappen L, Loken M. Multi-dimensional flow cytometric characterization of myeloid maturation in normal bone marrow and acute myeloid leukemia. In: Burger G, Oberholzer M, Vooijs G, editors. Advances in Analytical Cellular Pathology. Amsterdam, The Netherlands: Excerpta Medica; 1990. pp. 209–210.
    1. Wormann B SM, Konemann S, et al. Detection of residual leukemic cells in AML patients in complete remission [abstract]. Blood (ASH Annual Meeting Abstracts) 1991;78(11) Abstract 381.
    1. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90(6):2465–2470. - PubMed

Publication types

MeSH terms

Associated data